Lifevantage EV/EBIT LFVN

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026: 9.6×
10-year median: 10.8×
Against its 10-year history: 43rd; percentile: 0 is its lowest day, 100 its highest
10-year range: 2.3× to 49.1×
Peer median: 2.9×

Lifevantage's EV/EBIT is 9.6× as of Oct 23, 2026.

That is below its ten-year median of 10.8×, close to the middle of its last ten years.

Over that time it ranged from 2.3× in Apr 2022 to 49.1× in Jan 2025.

The median for 8 large drugmakers of a similar size is 2.9×.

EV/EBIT over time

median 10.8×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	9.6×	4.6×	17.2×
2025	5.4×	5.4×	49.1×
2024	34.0×	14.4×	36.7×
2023	15.6×	4.4×	18.3×
2022	4.5×	2.3×	4.8×
2021	3.4×	3.3×	7.3×
2020	7.0×	7.0×	18.6×
2019	18.4×	14.6×	25.0×
2018	16.8×	7.8×	20.4×
2017	16.2×	11.5×	19.7×
2016	12.8×	10.0×	19.7×
2015	15.5×	3.4×	15.5×
2014	6.3×	6.0×	11.8×
2013	9.9×	8.8×	17.7×
2012	8.4×	8.1×	16.8×

Against its peers

Companies in Drug Manufacturers - General nearest Lifevantage's size, closest first, today.

Company	EV/EBIT
LFVNLifevantage	9.6×
SPROSpero Therapeutics	2.1×
ATNMActinium Pharmaceuticals	1.2×
NATRNatures Sunshine Products	5.2×
ARVNArvinas	n/m
PBYIPuma Biotechnology	15.6×
IRWDIronwood Pharmaceuticals	3.5×
ZVRAZevra Therapeutics	2.9×
CRMDCorMedix	2.3×
Peer median	2.9×

Where Lifevantage ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Lifevantage

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.